ITI Pharma and Healthcare Fund - Direct Plan - Growth Option

Q: How much expense ratio is charged by ITI Pharma and Healthcare Fund - Direct Plan - Growth Option?

The expense ratio for ITI Pharma and Healthcare Fund - Direct Plan - Growth Option, or any other mutual fund, is the yearly fee you pay for managing your investments. As of 23 Mar 2026, the expense ratio charged by ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is typically around undefined %. This fee covers fund management, administrative, and other operational costs. It is relatively low compared to actively managed funds, reflecting its direct growth option.

Q: What is the AUM of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option?

As of 23 Mar 2026, the Assets Under Management (AUM) of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is approximately ₹221.7766 crore. The AUM can fluctuate based on market conditions and investor activity. It indicates the total value of assets managed by the fund.

Q: What is the NAV of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option?

The Net Asset Value (NAV) of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is updated daily and reflects the per-unit value of the fund's assets. As of 23 Mar 2026 , the NAV is around undefined per unit, but this value might change based on market performance and fund holdings.

Q: What is the PE and PB ratio of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option?

The PE ratio for ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is 62.74 and the PB ratio is 7.76. The PE ratio is calculated by dividing the market price by the earnings per share, whereas the PB ratio is calculated by dividing the stock price by the book value per share.

Q: What is the exit load of ITI Pharma and Healthcare Fund - Direct Plan - Growth Option?

The exit load for ITI Pharma and Healthcare Fund - Direct Plan - Growth Option is undefined% if units are redeemed within 30 days from the date of investment. After this period, no exit load is applicable. This fee is charged to discourage short-term trading and ensure long-term investment.

Equity

NAV

₹ 15.95

CAGR (3 Years)

21.87%

AUM (Cr)

₹ 221.78

Risk

Very High Risk

About ITI Pharma and Healthcare Fund - Direct Plan - Growth Option

The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies enga